These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Effects of prostaglandins and blockers of prostaglandin synthesis on the ductus arteriosus: animal and human studies. Heymann MA; Rudolph AM Adv Prostaglandin Thromboxane Res; 1978; 4():363-72. PubMed ID: 645512 [No Abstract] [Full Text] [Related]
28. [Treatment of ductus-dependent congenital heart diseases with prostaglandin E1]. Lillquist K Ugeskr Laeger; 1979 Jul; 141(28):1915-6. PubMed ID: 473414 [No Abstract] [Full Text] [Related]
29. [Prostaglandin E, metabolic ligand with clinical and therapeutic implications in some congenital heart diseases and pulmonary diseases in infants]. Olariu-Ungureanu A; Socaciu A; Săvulescu M; Stoica E; Atanasiu M; Velciu V Rev Pediatr Obstet Ginecol Pediatr; 1980; 29(1):23-32. PubMed ID: 6770437 [No Abstract] [Full Text] [Related]
32. Enteral feeding in neonates with prostaglandin-dependent congenital cardiac disease: international survey on current trends and variations in practice. Howley LW; Kaufman J; Wymore E; Thureen P; Magouirk JK; McNair B; da Cruz EM Cardiol Young; 2012 Apr; 22(2):121-7. PubMed ID: 21771388 [TBL] [Abstract][Full Text] [Related]
33. [Present state of therapy of congenital heart defects]. Loogen F Dtsch Med J; 1967 Oct; 18(20):601-8. PubMed ID: 5610706 [No Abstract] [Full Text] [Related]
34. Modified Blalock-Taussig shunt following long-term administration of prostaglandin E1 for ductus-dependent neonates with cyanotic congenital heart disease. Yokota M; Muraoka R; Aoshima M; Nomoto S; Shiraishi Y; Kyoku I; Kitano M; Shimada I; Nakano H; Ueda K J Thorac Cardiovasc Surg; 1985 Sep; 90(3):399-403. PubMed ID: 4033176 [TBL] [Abstract][Full Text] [Related]
35. Prostaglandins and the management of congenital heart disease. Taylor WJ; Alpert BS Am Fam Physician; 1982 Dec; 26(6):127-32. PubMed ID: 6890758 [TBL] [Abstract][Full Text] [Related]
36. Common congenital cyanotic heart defects--diagnosis and management. Ranjit MS J Indian Med Assoc; 2003 Feb; 101(2):71-2, 74. PubMed ID: 12841486 [TBL] [Abstract][Full Text] [Related]
37. Prolonged prostaglandin E1 infusion in an infant with cyanotic congenital heart disease. Lewis AB; Lurie PR Pediatrics; 1978 Apr; 61(4):534-6. PubMed ID: 662477 [TBL] [Abstract][Full Text] [Related]
38. Clinical use of prostaglandins and prostaglandin synthetase inhibitors in cardiac problems of the newborn. Olley PM; Coceani F; Rowe RD; Swyer PR Adv Prostaglandin Thromboxane Res; 1980; 7():913-6. PubMed ID: 6768235 [No Abstract] [Full Text] [Related]
39. [Long-term treatment using prostaglandin E2 in congenital heart defects with the pulmonary circulation being supplied by a patent ductus arteriosus]. Hruda J; Samánek M; First T; Vorísková M; Skovránek J Cesk Pediatr; 1985 May; 40(5):257-62. PubMed ID: 3860302 [No Abstract] [Full Text] [Related]
40. [The management of congenital heart diseases in childhood]. Tikanoja T; Pesonen E Duodecim; 1996; 112(18):1613-5. PubMed ID: 10596153 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]